hrp0086p2-p679 | Growth P2 | ESPE2016

Association between Growth Hormone Peak at a Stimulation Test and Pituitary Morphological Findings in Children with Growth Hormone Deficiency

Schmitt-Lobe Maria Claudia , Perini Lais Dadan , Salm Leticia

Background: GH deficiency (GHD) diagnosis includes clinical manifestations, laboratory tests and imaging. There are controversies about the validity of the GH stimulation test. A variety of stimulation tests are used in clinical practice. The biochemical definition of GHD has generally been considered to be a peak stimulated GH concentration <10 ng/ml.Objective: The aim of this study was to check if there is a statistically significant relation betwe...

hrp0082p1-d2-6 | Adrenals &amp; HP Axis | ESPE2014

Descriptive Analyses of Turner Syndrome

Kamrath Clemens , Hartmann Michaela , Boettcher Claudia , Wudy Stefan

Background: One major issue of newborn screening programs for 21-hydroxylase deficiency (21OHD) is the high rate of false-positive results, especially in preterm neonates. Urinary steroid analysis using gas chromatography–mass spectrometry (GC–MS) is used as a confirmatory diagnostic tool.Objective and Hypotheses: The objective of this study was to analyze diagnostic metabolite ratios in neonates and infants with and without 21OHD using GC&#150...

hrp0082p2-d2-335 | Diabetes (1) | ESPE2014

Insulin Therapy via Tubeless Patch Pump: Really an Alternative?

Boettcher Claudia , Schaefer Maike , Weiss Lucia , Wudy Stefan A

Background: For a few years now tubeless disposable patch pumps are available for insulin therapy.Objective and hypotheses: Alarmed by initially non explainable beginning metabolic decompensation of two children with type 1 diabetes during their hospital stay for the initial therapy adjustment with patch pumps and alarmed by patients’ reports of frequent premature pump changes and alarms, we decided to scrutinize the patch pumps under laboratory con...

hrp0084p2-426 | GH &amp; IGF | ESPE2015

The Acid-Labile Subunit Dose Matters? Response to Human GH Treatment in Patients with Acid-Labile Subunit Deficiency

Bechtold Susanne , Roeb Julia , Weissenbacher Claudia , Sydlik Carmen , Schmidt Heinrich

Background: In patients with acid-labile subunit (ALS) deficiency, the inability to build ternary complexes results in a marked reduction of circulating total IGF1. Height reduction by heterozygosity is about 1 SD in comparison to wild type. In homozygosity or compound heterozygosity a height loss of −2 to −2.5 SD occurs. This is suggestive of a gene-dose effect. How does treatment with human GH influence height development in relation...

hrp0084p2-510 | Pituitary | ESPE2015

Chronic Inappropriate Antidiuresis in Childhood: Experience with Tolvaptan

Gaudino Rossella , Piona Claudia , Morandi Grazia , Cavarzere Paolo , Brugnara Milena

Background: The syndrome of inappropriate antidiuresis (SIAD) is one of the most common causes of hyponatremia: it’s a disorder of sodium and water balance, characterized by urinary dilution impairment and hypotonic hyponatremia, in the absence of renal disease or any non-osmotic stimulus, able to induce antidiuretic hormone (ADH) release. SIAD can be manifestation of a wide range of diseases, including cancer, head trauma, hydrocephalus and epilepsy. Usually transient an...

hrp0084p3-678 | Bone | ESPE2015

Final Height in a Patient with Fanconi Syndrome and GH Deficiency Treated with GH

Schmitt-Lobe Maria Claudia , Salm Leticia , Dadan Lais

Background: The Fanconi syndrome (FS) and GH deficiency (GHD) is a rare association. The FS is a dysfunction in the proximal tubule that can be idiopathic or primary. This dysfunction leads to renal loss of bicarbonate, phosphate, glucose, potassium and amino acids. One of the clinical feature is a delay in body growth. The correction of acidosis can protect the loss of growth. According to the prevalence of idiopathic GHD, it would be expected that 1 in 4 000 patients and, wi...

hrp0084p3-1046 | Growth | ESPE2015

Final Height in Patients with and without Pituitary Abnormalities Detected by MRI and/or CT Treated with GH

Schmitt-Lobe Maria Claudia , Webster Paula , Webster Roberta

Background: GH deficiency (GHD) occurs due to different aetiologies, morphological abnormalities in pituitary, or mutations leading the individual to lose the genetic growth potential. The pituitary dysfunction can be as GHD alone or associated with other hormones deficiencies. Patients with abnormalities in pituitary may present a greater height loss than others and couldn’t reach the target height (TH) according to final height (FH).Objectives: To...

hrp0084p3-1211 | Thyroid | ESPE2015

Rectal Diluted Levothyroxine for the Treatment of Neonatal Hypothyroidism: An Alternative Route of Administration

Ybarra Marina , Pinheiro Claudia , Setian Nuvarte , Damiani Durval , Dichtcekennian Vae

Background: Most individuals with neonatal hypothyroidism present clinically asymptomatic or with few symptoms. Early treatment with oral levothyroxine prevents complications related to this disorder. We report a case of a male infant with Short Bowel syndrome (SBS) and congenital hypothyroidism (CH) treated with rectal levothyroxine.Case and presentations: A male patient with previous gastroschisis underwent multiple surgical approaches for small bowel ...

hrp0097p2-57 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Heterozygous mutations in SETD5 are associated with bone fragility

Blaschitz Alexandra , Aischwarya Rao Avula , Castiglioni Claudia , Balasubramanian Meena

Background: SET domain-containing 5 (SETD5) is an uncharacterized member of the protein lysine methyltransferase family, a group best known for its ability to methylate their substrate and, by that, regulate gene expression. Heterozygous pathogenic variants in SETD5 are known to cause neurodevelopmental delay. We present two children with pathogenic variants in SETD5 and vertebral fractures with low bone mass. Individual 1 This 15-year old male of Caucasian an...

hrp0097p1-86 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Measurements of Growth Hormone using dried blood spots in preterm neonates: reference values and longitudinal evaluation.

Federico Giacchetti , Orsenigo Chiara , Vizzari Giulia , Tarricone Silvia , Vantaggiato Chiara , Rodari Giulia , Napolitano Filomena , Sangiorgio Andrea , Morniroli Daniela , Colombo Lorenzo , Profka Eriselda , Collini Valentina , Risio Alessandro , Lorella Giannì Maria , Arosio Maura , Mantovani Giovanna , Mosca Fabio , Ceriotti Ferruccio , Vidali Matteo , Giavoli Claudia

Background and aim: Congenital growth hormone deficiency (cGHD) is a rare but life-threatening condition whose diagnosis is challenging in the absence of reliable reference values, both in healthy neonates and in preterm ones. We recently estimated GH reference interval in 1036 healthy, at-term newborns (HN) form dried blood spot samples using a previously validated analytical method.Aim: of this study is to provide valu...